Xiaoli Liu Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Liu EVLO stock SEC Form 4 insiders trading

Xiaoli has made over 1 trades of the Evelo Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 3,000 units of EVLO stock worth $15,510 on 1 December 2020.

The largest trade she's ever made was selling 3,000 units of Evelo Biosciences Inc stock on 1 December 2020 worth over $15,510. On average, Xiaoli trades about 1,000 units every 0 days since 2020.

You can see the complete history of Ms. Liu stock trades at the bottom of the page.

Xiaoli Liu biography

Xiaoli Jacqueline Liu serves as Principal Accounting Officer, Controller of the Company. She has served as the Company's Vice President, Finance and Controller since June 2019. Prior to joining the Company, Ms. Liu was Head of Finance at Boston Biomedical Inc, a biotechnology company, from December 2018 to March 2019. From 2015 to 2018, Ms. Liu held roles of increasing responsibility in finance and corporate development at Forma Therapeutics Inc., a biotechnology company. Ms. Liu also worked in various finance roles at Epizyme, Inc., Novartis Vaccine & Diagnosis Inc. and Novartis Institute of BioMedical Research. She is a Certified Public Accountant (CPA), and holds an MBA from Boston University and an MSA from Bentley University.

How old is Xiaoli Liu?

Xiaoli Liu is 45, she's been the Principal Accounting Officer e Controller of Evelo Biosciences Inc since 2020. There are 15 older and no younger executives at Evelo Biosciences Inc. The oldest executive at Evelo Biosciences Inc is Stephen J. Carriere, 66, who is the VP & Chief Accounting Officer.

What's Xiaoli Liu's mailing address?

Xiaoli's mailing address filed with the SEC is C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.

Insiders trading at Evelo Biosciences Inc

Over the last 6 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan, eVentures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.

What does Evelo Biosciences Inc do?

evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag

Complete history of Ms. Liu stock trades at Evelo Biosciences Inc

Evelo Biosciences Inc executives and stock owners

Evelo Biosciences Inc executives and other stock owners filed with the SEC include:

• Balkrishan Gill,
  President, Chief Executive Officer, Principal Financial Officer, Treasurer, Director
• Mark Bodmer,
  Chief Scientific Officer, President of Research and Development
• David Epstein,
  Chairman of the Board
• Theodose Melas-Kyriazi,
  Independent Director
• Nancy Simonian,
  Independent Director
• Lord Ara Darzi,
  Independent Director
• David Perry,
  Independent Director
• Juan Andres,
  Independent Director
• Duncan McHale,
  Chief Medical Officer
• Daniel Char,
  General Counsel, Secretary
• Xiaoli Liu,
  Principal Accounting Officer, Controller
• Leslie Wardwell-Scott Ph.D.,
  Head of Corp. Devel. & Strategic Integration
• Jessica Cotrone,
  VP & Head of Communications
• Daniel S. Char,
  Gen. Counsel & Sec.
• Kendra Sweeney,
  Head of Investor Relations & Capital Markets
• Dr. Chun Zhang,
  Head of Technical Operations
• Stephen J. Carriere,
  VP & Chief Accounting Officer
• Luca Scavo,
  CFO, Sr. VP & Treasurer
• Dr. Duncan McHale M.D., Ph.D.,
  Chief Medical Officer
• Dr. Balkrishan Gill Ph.D.,
  Pres, CEO & Director
• Julie Mc Hugh,
  Director
• Alexander C Reynolds,
  Director
• Jeffrey R. Moore,
  Director
• Kyriazi Theo Melas,
  Director
• Noubar Afeyan,
  Director
• Ventures Fund Iv General Pa...,
  
• Jose Carlos Gutierrez Ramos,
  Director
• Simba Gill,
  President & CEO
• Jonathan Poole,
  CFO
• Ventures Fund Iv General Pa...,
  
• Ventures Fund V General Par...,
  
• Robert L. Rosiello,
  Director
• Tonya Williams,
  Director
• Iain B. Mc Innes,
  Director
• Neil Graham,
  Chief Development Officer
• Ventures Fund Iv General Pa...,
  
• Ventures Fund Iv General Pa...,
  
• Jonathan B. Zung,
  Chief Development Officer
• John Hohneker,
  Director
• Stephen J Carriere,
  Principal Accounting Officer
• Mark D. Plinio,
  Chief Commercial Officer
• Luca Scavo,
  CFO
• Ventures Fund Iv General Pa...,
  
• Marella Thorell,
  Chief Financial Officer